Stock SVA SINOVAC BIOTECH LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sinovac Biotech Ltd.

Equities

SVA

AGP8696W1045

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 16:00:00 2019-02-22 EST 		5-day change 1st Jan Change
6.47 USD -0.31% Intraday chart for Sinovac Biotech Ltd. -.--% -.--%
04-29 Sinovac Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
01-18 Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital cancelled the acquisition of 10.04% stake in Sinovac Biotech Ltd. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 479.4 640 639.9 642.4 642.4 642.4
Enterprise Value (EV) 1 316.3 457.3 -400 -12,628 -10,596 -10,282
P/E ratio 20.6 x 15.8 x 6.66 x 0.09 x 6.49 x -6.09 x
Yield - - - - - -
Capitalization / Revenue 2.09 x 2.6 x 1.25 x 0.03 x 0.43 x 1.43 x
EV / Revenue 1.38 x 1.86 x -0.78 x -0.65 x -7.1 x -22.9 x
EV / EBITDA 6.29 x 6.23 x -1.82 x -0.72 x 34.5 x 26.8 x
EV / FCF -56.5 x 23.4 x -1.16 x -1.15 x 9.08 x 74.1 x
FCF Yield -1.77% 4.27% -86.5% -87% 11% 1.35%
Price to Book 1.95 x 2.18 x 0.86 x 0.07 x 0.07 x 0.07 x
Nbr of stocks (in thousands) 69,082 98,918 98,903 99,295 99,295 99,295
Reference price 2 6.940 6.470 6.470 6.470 6.470 6.470
Announcement Date 19-04-29 20-04-30 21-04-22 22-04-29 23-05-01 24-04-29
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 229.6 246.1 510.6 19,375 1,493 448.3
EBITDA 1 50.28 73.44 219.5 17,639 -307 -383.8
EBIT 1 45.39 68.86 215.8 17,554 -460.9 -524.3
Operating Margin 19.77% 27.98% 42.26% 90.6% -30.87% -116.96%
Earnings before Tax (EBT) 1 46.58 70.82 216.6 17,563 25.24 -153
Net income 1 21.78 44.93 110.4 8,467 113.9 -99.92
Net margin 9.48% 18.26% 21.61% 43.7% 7.63% -22.29%
EPS 2 0.3365 0.4096 0.9710 74.27 0.9973 -1.063
Free Cash Flow 1 -5.602 19.54 346 10,989 -1,166 -138.7
FCF margin -2.44% 7.94% 67.76% 56.72% -78.13% -30.94%
FCF Conversion (EBITDA) - 26.61% 157.64% 62.3% - -
FCF Conversion (Net income) - 43.49% 313.51% 129.78% - -
Dividend per Share - - - - - -
Announcement Date 19-04-29 20-04-30 21-04-22 22-04-29 23-05-01 24-04-29
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 163 183 1,040 13,270 11,238 10,924
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -5.6 19.5 346 10,989 -1,166 -139
ROE (net income / shareholders' equity) 15.4% 20.2% 25.2% 193% 0.66% -2.09%
ROA (Net income/ Total Assets) 8.48% 10.5% 11.5% 118% -1.87% -2.36%
Assets 1 256.8 429.1 963 7,197 -6,101 4,234
Book Value Per Share 2 3.560 2.970 7.520 93.70 89.70 87.40
Cash Flow per Share 2 2.220 1.540 10.50 117.0 43.00 12.70
Capex 1 5.61 10.6 127 720 394 145
Capex / Sales 2.44% 4.32% 24.97% 3.72% 26.38% 32.24%
Announcement Date 19-04-29 20-04-30 21-04-22 22-04-29 23-05-01 24-04-29
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
SINOVAC BIOTECH LTD. Stock Sinovac Biotech Ltd.
-.--% 642M
CSL LIMITED Stock CSL Limited
-3.93% 86.16B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.17B
BIOGEN INC. Stock Biogen Inc.
-16.48% 31.47B
UCB Stock UCB
+54.25% 25.24B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.58% 15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.87% 8.84B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-2.11% 7.93B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. SVA Stock
  4. Financials Sinovac Biotech Ltd.